购物车
- 全部删除
- 您的购物车当前为空
Letaplimab (IBI-188) 是一种靶向 CD47 的人源化IgG4类抗体,常联合阿扎胞苷治疗初诊中高危骨髓增生异常综合症。
为众多的药物研发团队赋能,
让新药发现更简单!
Letaplimab (IBI-188) 是一种靶向 CD47 的人源化IgG4类抗体,常联合阿扎胞苷治疗初诊中高危骨髓增生异常综合症。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 2,480 | 现货 | |
5 mg | ¥ 6,470 | 现货 | |
10 mg | ¥ 8,720 | 现货 | |
25 mg | ¥ 12,900 | 现货 | |
50 mg | ¥ 17,300 | 现货 |
产品描述 | Letaplimab (IBI-188) is a humanized IgG4 class antibody targeting CD47 and is often used in combination with azacitidine for the treatment of primary diagnosis of intermediate- to high-risk myelodysplastic syndromes. |
别名 | 莱特利单抗, IBI-188, IBI188 |
CAS No. | 2283356-07-8 |
存储 | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容